Michael Gelband’s Medifast MED Stock Holding History

Michael Gelband’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-54,175	Closed	-$1.18M	–	1898
2024 Q2	$1.18M	Buy	+54,175	New	+$1.44M	0.01%	964
2023 Q4	–	Sell	-6,391	Closed	-$478K	–	1821
2023 Q3	$478K	Buy	+6,391	New	+$567K	﹤0.01%	1259
2023 Q2	–	Sell	-7,116	Closed	-$738K	–	2097
2023 Q1	$738K	Buy	+7,116	New	+$789K	0.01%	1236
2021 Q4	–	Sell	-7,428	Closed	-$1.43M	–	2434
2021 Q3	$1.43M	Sell	7,428 -288	-4%	-$70.8K	0.02%	872
2021 Q2	$2.18M	Buy	7,716 +8	+0.1%	+$2.17K	0.02%	641
2021 Q1	$1.63M	Buy	7,708 +5,168	+203%	+$1.24M	0.02%	651
2020 Q4	$499K	Sell	2,540 -575	-18%	-$102K	﹤0.01%	1254
2020 Q3	$512K	Buy	+3,115	New	+$513K	0.01%	1001
2019 Q4	–	Sell	-8,327	Closed	-$863K	–	1736
2019 Q3	$863K	Sell	8,327 -2,156	-21%	-$232K	0.03%	434
2019 Q2	$1.34M	Buy	+10,483	New	+$1.46M	0.05%	208

Other funds holding MED

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's MED Position: Q3 2024 in Review

Michael Gelband sold out of Medifast (MED) in Q3 2024, closing a stake of 54,175 shares — an estimated $1.18M sold.

Michael Gelband first reported a position in MED in Q2 2019 and held it in 10 quarters. The position peaked at $2.18M in Q2 2021. 140 funds tracked by Wall St. Rank hold MED as of Q3 2024.

Michael Gelband reported no remaining Medifast position as of Q3 2024 after selling out during the quarter.
Michael Gelband sold 54,175 Medifast shares in Q3 2024, an estimated $1.18M.
Michael Gelband first reported a position in Medifast in Q2 2019 and held it in 10 quarters.
Michael Gelband's Medifast position peaked at $2.18M in Q2 2021.
140 funds tracked by Wall St. Rank held Medifast as of Q3 2024.

Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.